title: Sustained NF-κB activation and inhibition in β-cells have minimal effects on function and islet transplant outcomes.
abstract: The activation of the transcription factor NF-κB leads to changes in expression of many genes in pancreatic β-cells. However, the role of NF-κB activation in islet transplantation has not been fully elucidated. The aim of the present study was to investigate whether the state of NF-κB activation would influence the outcome of islet transplantation. Transgenic mice expressing a dominant active IKKβ (constitutively active) or a non-degradable form of IκBα (constitutive inhibition) under control of the rat insulin promoter were generated. Islets from these mice were transplanted into streptozotocin diabetic mice in suboptimal numbers. Further, the effects of salicylate (an inhibitor of NF-κB) treatment of normal islets prior to transplantation, and the effects of salicylate administration to mice prior to and after islet implantation were evaluated. Transplantation outcomes were not affected using islets expressing a non-degradable form of IκBα when compared to wild type controls. However, the transplantation outcomes using islets isolated from mice expressing a constitutively active mutant of NF-κB were marginally worse, although no aberrations of islet function in vitro could be detected. Salicylate treatment of normal islets or mice had no effect on transplantation outcome. The current study draws attention to the complexities of NF-κB in pancreatic beta cells by suggesting that they can adapt with normal or near normal function to both chronic activation and inhibition of this important transcription factor.
authors.affiliation: Diabetes Research Group, King's College London, London, United Kingdom ; Section on Islet Cell and Regenerative Biology, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, United States of America.
authors.forename: Aileen J F
authors.initials: AJ
authors.lastname: King
authors.forename: Yongjing
authors.initials: Y
authors.lastname: Guo
authors.forename: Dongsheng
authors.initials: D
authors.lastname: Cai
authors.forename: Jennifer
authors.initials: J
authors.lastname: Hollister-Lock
authors.forename: Brooke
authors.initials: B
authors.lastname: Morris
authors.forename: Alison
authors.initials: A
authors.lastname: Salvatori
authors.forename: John A
authors.initials: JA
authors.lastname: Corbett
authors.forename: Susan
authors.initials: S
authors.lastname: Bonner-Weir
authors.forename: Steven E
authors.initials: SE
authors.lastname: Shoelson
authors.forename: Gordon C
authors.initials: GC
authors.lastname: Weir
mesh_terms: D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000235:genetics / Q000378:metabolism* / Q000628:therapy; D005260:Female; D005786:Gene Expression Regulation; D051550:I-kappa B Kinase / Q000235:genetics / Q000378:metabolism*; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D016381:Islets of Langerhans Transplantation; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism*; D011401:Promoter Regions, Genetic; D051381:Rats; D020156:Salicylic Acid / Q000008:administration & dosage; D013311:Streptozocin; D016896:Treatment Outcome
chemical_list: D016328:NF-kappa B; D013311:Streptozocin; C496564:Chuk protein, mouse; D051550:I-kappa B Kinase; D020156:Salicylic Acid